Drug Profile
Dexmedetomidine - BioXcel Therapeutics
Alternative Names: BXCL-501; Dex-BioXcel Therapeutics; IGALMI; KalmPen™; Sublingual film containing IgalmiLatest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator Inveni
- Developer BioXcel Therapeutics
- Class Antidepressants; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Drug withdrawal therapies; Hypnosedatives; Imidazoles; Non-opioid analgesics; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Agitation
- Phase I/II Opioid-related disorders
- Phase I Alcoholism; Major depressive disorder; Post-traumatic stress disorders
Most Recent Events
- 15 Mar 2024 BioXcel Therapeutics receives notice that the USPTO has allowed US patent application for method of treating agitation using an oromucosal formulation of dexmedetomidine
- 13 Mar 2024 BioXcel Therapeutics has a patent protection for method of treating agitation in dementia using sublingual dexmedetomidine in Europe
- 06 Mar 2024 BioXcel Therapeutics holds Type C meeting with the US FDA for dexmedetomidine in Agitation (associated with bipolar disorders or schizophrenia)